COMP <GO>
NUS vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Nu Skin Enterprises Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NUS 2
— MRK 8
■ METRIC PARITY
LAST: $4.65 (-0.85%) • MKT CAP: $228.3M
options-implied-move
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.40% | 74.80% | -5.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 20.70% | -14.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 20.15% | 3.42% | +16.73 | NUS | /fcf-yield <GO> |
| Operating Margin | 4.40% | 34.30% | -29.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 28.10% | -17.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -14.30% | 1.30% | -15.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.18% | 2.26% | +2.92 | NUS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.19 | -1.65 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 51.7 | -6.50 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $228.3M | $361.02B | -$360.79B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUS REV | MRK REV | NUS GROSS % | MRK GROSS % | NUS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.49B | $65.01B | 69.4% | 74.8% | $46.0M | $12.36B |
| FY 2024 | $1.73B | $64.17B | 68.2% | 76.3% | $70.2M | $18.10B |
| FY 2023 | $1.97B | $60.12B | — | — | $118.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUS // BETA —
MRK // BETA 0.92